Omeros (OMER) said Tuesday that it has begun commercial sales of Yartemlea following initial shipments to distributors and early use by transplant centers in the US.

Financial details related to early sales were not provided.

The company said that orders were received and filled last week, and that the drug is now being given to both adult and pediatric patients with transplant-associated thrombotic microangiopathy, including those treated in hospitals and outpatient settings.

Omeros said Yartemlea received US Food and Drug Administration approval last month and is cleared for patients aged two years and older.

Omeros said an application seeking European approval for Yartemlea is under review by regulators, with a decision expected in mid-2026.

Price: 11.56, Change: +0.03, Percent Change: +0.22